Hong Kong
Every company in the roster headquartered in Hong Kong.
Every company in the roster headquartered in Hong Kong.
4 of 4 companies
| Company | Pipeline | Most advanced | Next readout | Market cap | Cash & inv. | Runway | R&D / yr |
|---|---|---|---|---|---|---|---|
HUTCHMEDHCM · Nasdaq | 2 assets: 1 approved, 1 Ph 3 | SavolitinibPhase 3 · Non-Small Cell Lung CancerPartial signal | 18 Jan 2027Savolitinib · Phase 2 | $2.4B | $1.4BDec 2025 | 10+ years | $148M |
Essex Bio-Technology Limited1061 · HKEX | 1 asset: 1 Ph 3 | HLX04-OPhase 3 · Age-Related Macular DegenerationPartial signal | None on record | — | — | — | — |
Lee's Pharmaceutical0950 · HKEX | 4 assets: 2 Ph 3, 1 Ph 2, 1 other | Loxapine (Adasuve)Phase 3 · SchizophreniaReliable signal | Dec 2028Istaroxime · Phase 2/3 | — | $45MDec 2025 | — | $14M |
Tenacia BiotechnologyPrivate | 1 asset: 1 Ph 3 | RAP-219Phase 3 · EpilepsyWeak signal | Jun 2027RAP-219 · Phase 1 | — | — | — | — |
Next readout: the earliest estimated primary completion of a trial the company or a partner on the asset runs (ClinicalTrials.gov). Cash shows its balance-sheet month; runway shows a month only when it comes from an earlier report.